AR088963A1 - Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina - Google Patents

Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina

Info

Publication number
AR088963A1
AR088963A1 ARP120104403A ARP120104403A AR088963A1 AR 088963 A1 AR088963 A1 AR 088963A1 AR P120104403 A ARP120104403 A AR P120104403A AR P120104403 A ARP120104403 A AR P120104403A AR 088963 A1 AR088963 A1 AR 088963A1
Authority
AR
Argentina
Prior art keywords
salt
hyaluronic acid
sulfate
complex
condroitine
Prior art date
Application number
ARP120104403A
Other languages
English (en)
Inventor
Agut Sanchez Julian
Fernandez Navarro Carlos
Cos Trullas Joan
Ocaa Safont Laura
Original Assignee
Quimera Ingenieria Biomedica S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45093470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR088963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quimera Ingenieria Biomedica S L filed Critical Quimera Ingenieria Biomedica S L
Publication of AR088963A1 publication Critical patent/AR088963A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente se refiere a un complejo obtenible mezclando ácido hialurónico o una sal del mismo y sulfato de condroitina o una sal del mismo, y formando una disolución acuosa de dicha mezcla, que se somete a un proceso de secado adicional. También se refiere a diversas composiciones y formulaciones que comprenden el complejo, al procedimiento para obtener dicho complejo y a usos del mismo. Reivindicación 1: Complejo obtenible mediante: a) mezclar ácido hialurónico o una sal del mismo con sulfato de condroitina o una sal del mismo, b) formar una disolución acuosa de dicha mezcla, y c) atomizar la disolución acuosa resultante, en el que el ácido hialurónico o una sal del mismo tiene un peso molecular promedio superior a 1.000.000 Dalton, y el sulfato de condroitina o una sal del mismo tiene un peso molecular promedio de desde 5.000 hasta 50.000 Dalton.
ARP120104403A 2011-11-24 2012-11-23 Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina AR088963A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11190532.9A EP2596796B1 (en) 2011-11-24 2011-11-24 Complex obtained from hyaluronic acid or a salt thereof and chondroitin sulphate mixtures

Publications (1)

Publication Number Publication Date
AR088963A1 true AR088963A1 (es) 2014-07-23

Family

ID=45093470

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120104403A AR088963A1 (es) 2011-11-24 2012-11-23 Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina

Country Status (12)

Country Link
US (1) US8980866B2 (es)
EP (1) EP2596796B1 (es)
AR (1) AR088963A1 (es)
BR (1) BR102012029737B1 (es)
CL (1) CL2012003287A1 (es)
CO (1) CO6590210A1 (es)
DK (1) DK2596796T3 (es)
ES (1) ES2444145T3 (es)
MX (1) MX2012013610A (es)
PE (1) PE20130728A1 (es)
PL (1) PL2596796T3 (es)
RS (1) RS53135B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9492474B2 (en) 2013-07-10 2016-11-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
ITUB20152542A1 (it) * 2015-07-28 2017-01-28 Altergon Sa Formulati oftalmici a base di complessi cooperativi di acido ialuronico a basso e alto peso molecolare
PT3352766T (pt) * 2015-09-24 2022-03-22 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
RU2612014C1 (ru) * 2015-10-19 2017-03-01 Общество с ограниченной ответственностью "ДИАМЕД-фарма" Средство для лечения артрологических заболеваний
JP6847866B2 (ja) * 2016-01-29 2021-03-24 生化学工業株式会社 コンドロイチン硫酸及びヒアルロン酸を含有する安定化された水性組成物
KR20180035032A (ko) * 2016-09-28 2018-04-05 주식회사 파마리서치프로덕트 가교 히알루론산을 포함하는 주사용 조성물
IT201900008409A1 (it) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci
CN113041405B (zh) * 2021-03-22 2022-06-10 山东华熙海御生物医药有限公司 一种含透明质酸和四氢嘧啶的人体润滑液及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU555747B2 (en) 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
US6051560A (en) * 1986-06-26 2000-04-18 Nestle S.A. Chrondroitin sulfate/sodium hyaluronate composition
EP1267894B1 (en) 2000-03-14 2010-05-05 Alcon Inc. Viscoelastics for use in middle ear surgery
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
US7820194B2 (en) 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
US7956180B2 (en) * 2004-05-27 2011-06-07 Novozymes A/S Dried and agglomerated hyaluronic acid product
EA018333B1 (ru) 2008-05-13 2013-07-30 Афарм С.Р.Л. Применение гликозаминогликанов для перорального введения и композиции гликозаминогликанов
IT1402382B1 (it) 2010-09-09 2013-09-04 Ibsa Inst Biochimique Sa Complessi cooperativi ibridi di acido ialuronico

Also Published As

Publication number Publication date
EP2596796A1 (en) 2013-05-29
ES2444145T3 (es) 2014-02-24
BR102012029737A2 (pt) 2015-11-03
CO6590210A1 (es) 2013-01-02
US8980866B2 (en) 2015-03-17
EP2596796B1 (en) 2013-11-13
DK2596796T3 (da) 2014-01-27
US20130143838A1 (en) 2013-06-06
CL2012003287A1 (es) 2013-06-07
PL2596796T3 (pl) 2014-04-30
PE20130728A1 (es) 2013-06-27
RS53135B (en) 2014-06-30
BR102012029737B1 (pt) 2020-10-27
MX2012013610A (es) 2013-05-23

Similar Documents

Publication Publication Date Title
AR088963A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
CY1119433T1 (el) Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες
BR112015006100A2 (pt) microcápsulas produzidas por secagem por atomização
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
CL2016001150A1 (es) Formas sólidas de ácido [(5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]aético, composiciones, y usos de las mismas.
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
IN2015KN00262A (es)
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
BR112014029754B1 (pt) soluções de tensoativos que contêm n-metil-noleilglucaminas e n-metil-n-c12-c14 acilglucaminas e seu uso, processo para produzir composições cosméticas e composição
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
AR087060A1 (es) Particulas cristalinas recubiertas de micelas
BR112017013483A2 (pt) composição em pó, processo para preparação de partículas de bicarbonato de metal alcalino, uso de um aminoácido como aditivo, e, uso de uma composição em pó.
MX2021010060A (es) Produccion de virus en huevos aviares.
RU2015140720A (ru) Некодирующий иммуномодулирующей конструкт днк с ковалентно закрытой структурой
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
EA201792023A3 (ru) Фармацевтические составы, содержащие хондроитин сульфат и производные гиалуроновой кислоты
WO2015033302A3 (en) Fulvestrant compositions
BR112016022394A2 (pt) Composição farmaceuticamente aceitável, composição na forma de uma solução injetável farmaceuticamente aceitável, uso da composição, e, método para a preparação da composição injetável farmaceuticamente aceitável
UY35848A (es) Tienopirimidinas
BR112014010374A2 (pt) alimento para animais, uso de uma xilanase hiper-termofílica e hiper-termoestável, uso do alimento para animais e processo para produzir alimento para animais
EA201490032A1 (ru) Лиофилизированные препараты fgf-18
WO2012175742A3 (en) Methods for the production of a cosmetic composition comprising leukolectin and uses thereof
CL2015002376A1 (es) Fibra de madera acetilada

Legal Events

Date Code Title Description
FG Grant, registration